Japan 2014: Regulatory Moves, Suspect Practices, And Acquisitions
This article was originally published in PharmAsia News
Executive Summary
If you missed any of the major news and analysis from Japan in 2014, here's your opportunity to check out PharmAsia News' view of the most important stories of the year. If there was any one overriding trend to pick out, it was the push towards more efficient regulation and the shaping of policy to support medical research in a rapidly aging society.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.